Ciprofibrate is a lipid-lowering agent belonging to the class of fibric acid derivatives. It is primarily used to treat hypertriglyceridemia and mixed dyslipidemia by reducing elevated triglyceride and cholesterol levels. Ciprofibrate works by activating the peroxisome proliferator-activated receptor alpha (PPAR-α), which enhances the breakdown of fatty acids and improves lipid metabolism. It helps increase high-density lipoprotein (HDL) cholesterol while lowering very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol. The drug is orally administered and is well absorbed in the gastrointestinal tract. Ciprofibrate has been extensively studied for its efficacy and safety in managing cardiovascular risk associated with dyslipidemia. In pharmaceutical analysis, it is important to ensure its purity, identity, and potency. Chromatographic methods are commonly used for its routine quality control and system suitability testing. Reference standards of ciprofibrate are employed to validate analytical methods and confirm accurate dosage. Overall, ciprofibrate plays a crucial role in both therapeutic management of lipid disorders and pharmaceutical quality assurance.
